Alyeska Investment Group L.P. Has $3.80 Million Stock Holdings in Nkarta, Inc. $NKTX

Key Points

• Alyeska Investment Group L.P. has increased its stake in Nkarta, Inc. by 54.7%, owning a total of 2,064,956 shares valued at approximately $3.8 million as of the latest quarter.
• Several institutional investors have also boosted their holdings in Nkarta, contributing to institutional ownership of 80.54% of the company's stock.
• Analysts have given Nkarta a consensus rating of "Buy", with an average price target of $13.60 following recent upgrades and adjustments.

Alyeska Investment Group L.P. raised its holdings in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 54.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,064,956 shares of the company's stock after purchasing an additional 730,260 shares during the period. Alyeska Investment Group L.P. owned approximately 2.91% of Nkarta worth $3,800,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Nkarta by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 31,056 shares of the company's stock valued at $77,000 after buying an additional 6,763 shares during the period. Dimensional Fund Advisors LP raised its holdings in Nkarta by 101.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company's stock valued at $1,417,000 after acquiring an additional 286,181 shares in the last quarter. Stifel Financial Corp raised its holdings in Nkarta by 11.5% in the 4th quarter. Stifel Financial Corp now owns 90,811 shares of the company's stock valued at $226,000 after acquiring an additional 9,359 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Nkarta by 102.8% during the 4th quarter. Hsbc Holdings PLC now owns 73,845 shares of the company's stock valued at $171,000 after acquiring an additional 37,433 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Nkarta by 41.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after purchasing an additional 7,030 shares in the last quarter. 80.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on NKTX. Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Nkarta in a research report on Wednesday, August 13th. Stifel Nicolaus decreased their target price on shares of Nkarta from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Wall Street Zen raised shares of Nkarta from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. William Blair reiterated a "market perform" rating on shares of Nkarta in a research report on Thursday, May 15th. Finally, Mizuho lowered their price objective on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $13.60.

Nkarta Price Performance

NKTX stock traded up $0.05 during trading on Thursday, reaching $2.07. 434,867 shares of the company were exchanged, compared to its average volume of 519,128. The company has a market capitalization of $147.03 million, a price-to-earnings ratio of -1.40 and a beta of 0.76. The company has a 50-day moving average of $2.08 and a two-hundred day moving average of $1.89. Nkarta, Inc. has a twelve month low of $1.31 and a twelve month high of $6.49.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. On average, analysts forecast that Nkarta, Inc. will post -1.7 EPS for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.